Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Danaher Corporation (DHR) - $25 value - yours FREE >>
MRC Global Inc. (MRC) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Corporation (DHR) - $25 value - yours FREE >>
MRC Global Inc. (MRC) - $25 value - yours FREE >>
Image: Shutterstock
Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance
Danaher Corporation (DHR - Free Report) is set to provide an update on its fourth-quarter 2022 guidance at the J.P. Morgan Healthcare Conference today.
For the fourth quarter, the company expects revenues to increase in the low-single-digit percent range from the year-ago quarter’s level. Adjusted core revenue growth is anticipated to be in the high-single-digit percent range against the flat to a low-single-digit percent decline stated earlier. Danaher maintains its adjusted base business core revenue growth in the high-single digit percent range for the fourth quarter.
DHR’s president and chief executive officer, Rainer M. Blair said that the company’s fourth-quarter performance benefited from strong growth in the Cepheid's molecular diagnostics business, thanks to respiratory testing revenues of more than $1 billion.
Strength in the Life Sciences segment owing to robust activity in the bioprocessing business and growth in instrument businesses are likely to have aided Danaher’s fourth-quarter performance. However, high raw material and freight costs, and supply chain disruptions are likely to have affected DHR’s margin performance in the quarter.
Danaher Corporation Price
Danaher Corporation price | Danaher Corporation Quote
Danaher is scheduled to release fourth-quarter 2022 earnings numbers on Jan 24.
Zacks Rank & Stocks to Consider
DHR currently carries a Zacks Rank #4 (Sell).
Some better-ranked companies are discussed below:
Xylem Inc. (XYL - Free Report) presently sports a Zacks Rank of #1 (Strong Buy). XYL’s earnings surprise in the last four quarters was 13.3%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
In the past 60 days, Xylem’s earnings estimates have increased 0.1% for 2022. The stock has gained 43% in the past six months.
MRC Global Inc. (MRC - Free Report) presently has a Zacks Rank #2 (Buy). MRC’s earnings surprise in the last four quarters was 103%, on average.
In the past 60 days, MRC Global’s earnings estimates have increased 16.2% for 2022. The stock has gained 13.4% in the past six months.
EnerSys (ENS - Free Report) delivered an average four-quarter earnings surprise of 2.1%. ENS presently carries a Zacks Rank of 2.
ENS’ earnings estimates have increased 0.6% for fiscal 2023 in the past 60 days. The stock has gained 30.6% in the past six months.